Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20252024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Reports First Quarter 2021 Financial Results May 06, 2021 Nektar to Announce Financial Results for the First Quarter 2021 on Thursday, May 6, 2021, After Close of U.S.-Based Financial Markets Apr 27, 2021 Nektar Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results Feb 25, 2021 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2020 on Thursday, February 25, 2021, After Close of U.S.-Based Financial Markets Feb 18, 2021 Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) Feb 17, 2021 Nektar Announces Collaboration with SFJ Pharmaceuticals® for Bempegaldesleukin in Head and Neck Cancer Feb 17, 2021 Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference Jan 06, 2021 Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development Jan 05, 2021 Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million Dec 22, 2020 Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer Dec 15, 2020 Pagination First page « first Previous page ‹ previous … Page 5 Page 6 Page 7 Page 8 Current page 9 Page 10 Page 11 Page 12 Page 13 … Next page next › Last page last »